Search Results
Results found for "Jurgen Wess"
- 📅 Dr. GPCR Summit 2022 is less than a month away!
GPCR Summit 2022 is less than a month away!
- Carola Weiss joins InterAx Biotech AG as VP Business Development
February 2022 "Switzerland Today, InterAx Biotech is pleased to announce that Carola Weiss has joined Carola Weiss is a Senior Executive with more than 20 years of international experience in the biopharmaceutical Carola Weiss’ professional career brings deep expertise in business development, marketing & sales, licensing
- 📰 GPCR Weekly News, June 3 to June 9, 2024
Jürgen Wess and Liu Liu for their study on A novel function of the M2 muscarinic receptor Drs.
- Why Sokhom Pin Never Left GPCRs, Even When Everyone Else Did
Now, there’s less competition and more opportunity.”
- From One to Many: How a GPCR Curiosity Became a Field-Wide Toolkit
In fact, it all began with a phone call (from Bruce Merrifield, no less) encouraging Sakmar to work on
- Nanobodies: New Dimensions in GPCR Signaling Research
C., Wess, J., & Kobilka, B. K. (2013).
- Chemical Drug Matter : Rethinking the Molecules We Choose to Develop In Drug Discovery
Yet, far less time is spent scrutinizing the structural logic and origin of the molecules we screen Less than ~15% of higher plant species, <5% of bacterial and fungal species, and only a fraction of marine
- X4 slashes pipeline, lays off staff just three weeks after netting a $55M PIPE
The move comes less than three weeks after X4 pulled together a $55 million PIPE and amended a loan facility
- G protein-coupled receptor signaling: transducers and effectors
We will first summarize their prominent roles in GPCR pharmacology before transitioning into less well-explored
- Fentanyl and Xylazine: Why Breathing Fails in Overdose
through the mu-opioid receptor, blunts the brainstem’s inspiratory drive so that each breath draws in less two drugs, there was a potentiation of fentanyl’s effect on tidal volume—mice were bringing in even less
- The Quiet Power of RGS Proteins: Rethinking Pain Pathways through GPCR Biology
Serafini’s work on RGS proteins suggests a quieter, but no less powerful, frontier in the fight against
- Opioid Ligands Addressing Unconventional Binding Sites and More Than One Opioid Receptor Subtype
In a constant effort to develop drugs with less side effects, and tools to explore the ORs nature and
- The complicated lives of GPCRs in cardiac fibroblasts
Here, we will focus on the relatively less well-studied effects of GPCRs in cardiac fibroblasts, focusing
- Nanobodies as Probes and Modulators of Cardiovascular G Protein-Coupled Receptors
In less than a decade, nanobodies, or recombinant single-domain antibody fragments from camelids, have
- Why Biotech Fundraising Fails Due to Intellectual Property Gaps
Less attention is placed on legal volume, and more on strategic coherence. When science, IP, and business reinforce each other, fundraising conversations move faster and with less
- Newly launched antibody libraries put hard-to-drug targets within reach
November 2021 "Target class-specific libraries mean you need to screen less to identify high-quality
- Early Stage Biotech Hiring: What Really Holds a Team Together When the Science Starts to Drift
What they are less prepared for is how much this uncertainty tests the team. When founders make this shift, hiring becomes less about finding the perfect profile and more about building
- From GPCR Data Chaos to Decisive Action
They stall because the data becomes a mess.
- Induced Human Regulatory T Cells Express the Glucagon-like Peptide-1 Receptor
In contrast, less is known about the expression and function of the GLP-1R in human T cells.
- AlphaFold’s Breakthrough in GPCR Research: Revolutionizing Discovery, Yet Awaiting Experimental Proof
For proteins with low sequence similarity to available templates, homology models tend to be less accurate
- Reflections on My PhD Journey: Lessons Learned
ensures that you remain on top of your findings but also makes the thesis-writing process significantly less
- Canonical chemokine receptors as scavenging “decoys”
Although less characterized, canonical CKRs have also been shown to not only directly regulate migration
- From Pipettes to Platforms: The Evolution of GPCR Research
Today, success depends less on manual precision and more on experimental design, data interpretation,
- Dynamic GPCR activation revealed through time-resolved Cryo-EM
dynamics of GPCR activation has always been a challenge because G protein activation in cells occurs in less
- How Breakthroughs Happen: Eric Trinquet on Innovation, Serendipity & GPCRs
It began with an unmet need: how to track Gq-coupled GPCR activity without the mess of calcium flux or
- Purpose-Driven Opioid Research: Catherine Demery’s Academic Path
Academic success is less about prestige than about impact.
- Targeted Drug Design through GPCR Mutagenesis: Insights from β2AR
Understanding the evolutionary conservation of these residues can lead to the development of drugs that are less
- When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue
Model That Makes GPCR Imaging Possible Behind every technical advance in this story sits something less
- Decoding Schild Analysis: The Pharmacologist’s Lens on Competitive Antagonism
Extending Schild to Partial Agonists Partial agonists complicate things—they activate receptors but less
- Accelerating GPCR Drug Discovery: What 40 Years of Pharmacology Reveal
It’s less bureaucratic than most outsiders think.

















